LC
ALXO icon

Lindbrook Capital’s ALX Oncology ALXO Stock Holding History

Lindbrook Capital’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-282
Closed -$1.7K – 2827
2024
Q2 		$1.7K Hold
282
– – ﹤0.01% 2393
2024
Q1 		$3.14K Hold
282
– – ﹤0.01% 2084
2023
Q4 		$4.2K Buy
+282
New +$2.67K ﹤0.01% 1979
2023
Q1 		– Sell
-215
Closed -$2.42K – 2775
2022
Q4 		$2.42K Hold
215
– – ﹤0.01% 2160
2022
Q3 		$2K Hold
215
– – ﹤0.01% 1976
2022
Q2 		$2K Buy
215
+81
+60% +$882 ﹤0.01% 1900
2022
Q1 		$2K Buy
+134
New +$2.29K ﹤0.01% 1930
2021
Q4 		– Sell
-400
Closed -$30K – 2062
2021
Q3 		$30K Sell
400
-800
-67% -$53.3K 0.01% 595
2021
Q2 		$66K Buy
+1,200
New +$71.8K 0.01% 387
2021
Q1 		– Sell
-700
Closed -$60K – 1867
2020
Q4 		$60K Buy
700
+550
+367% +$33.1K 0.01% 350
2020
Q3 		$6K Buy
+150
New +$5.9K ﹤0.01% 1000

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's ALXO Position: Q3 2024 in Review

Lindbrook Capital sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 282 shares — an estimated $1.7K sold.

Lindbrook Capital first reported a position in ALXO in Q3 2020 and held it in 11 quarters. The position peaked at $66K in Q2 2021. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

  • Lindbrook Capital reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
  • Lindbrook Capital sold 282 ALX Oncology shares in Q3 2024, an estimated $1.7K.
  • Lindbrook Capital first reported a position in ALX Oncology in Q3 2020 and held it in 11 quarters.
  • Lindbrook Capital's ALX Oncology position peaked at $66K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.